Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Priftin

(Rifapentine)

ApprovedSmall molecule

Rifapentine is used to treat tuberculosis (TB), a serious lung infection. It works by killing the bacteria that cause TB and is often used as part of a combination treatment with other TB medications.[2] Priftin is currently approved and in use across 5 indications[4].[1]

Priftin is one of 176 small molecule programs targeting Macular Degeneration. It is currently in Approved.

5

Indications

33

Total Trials

7

Active Trials

175

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Macular DegenerationActive, not recruiting

Pulmonary TuberculosisApproved

OsteomyelitisApproved

HIVTerminated

TuberculosisActive, not recruiting

Macular DegenerationPreclinical

Active, not recruiting

Pulmonary TuberculosisApproved

Approved

OsteomyelitisApproved

Approved

HIVPhase 2

Terminated

TuberculosisApproved

Active, not recruiting

Competition

Competitive Landscape

297 competitors in Tuberculosis

#DrugCompanyPhaseTrials

Priftin

Emtriva

Ziagen

Sitafloxacin

Ethambutol Hydrochloride

Contezolid

RHB-104

RRedHill Biopharma Limited

Isoniazid for 9 Months

NNational Taiwan University Hospital

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Tivicay

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Prevention

NCT06281834

Q3 2027

Phase 3Recruiting

Children

NCT06253715

Q4 2027

Phase 3Not yet recruiting

Tuberculosis

NCT06191692

Q2 2028

Phase 1/2Not yet recruiting

Tuberculosis

NCT07124559

Clinical

Trials by Indication[1]

Tuberculosis15 trials

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

Completed·UUniversity College, London·Phase 2/3·NCT03474198·675 enrolled

Tuberculosis Clinical Trials Consortium Study 35

Completed·CCenters for Disease Control and Prevention·Phase 1/2·NCT03730181·62 enrolled

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT02563327·53 enrolled

Show 12 more trials

A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT07124559·144 enrolled

Tuberculosis Prevention for HIV Infected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00057122·1,148 enrolled

Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT05454345·620 enrolled

Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings

Completed·YYale University·N/A·NCT03089983·316 enrolled

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT02410772·2,516 enrolled

TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT00023335·1,000 enrolled

Treatment of Latent Tuberculosis in Socially Marginalised Citizens

Terminated·—·Phase 4·NCT03266991·22 enrolled

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Completed·CCenters for Disease Control and Prevention·Phase 2·NCT00694629·865 enrolled

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Not yet recruiting·SShandong University·Phase 2·NCT06917495·300 enrolled

TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis

Completed·CCenters for Disease Control and Prevention·Phase 2·NCT00023426·150 enrolled

1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam

Not yet recruiting·FFreundeskreis Für Internationale Tuberkulosehilfe e.V·Phase 3·NCT06191692·350 enrolled

TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children Receiving Once Weekly Rifapentine and Isoniazid for the Treatment of Latent Tuberculosis Infection

Completed·CCenters for Disease Control and Prevention·Preclinical·NCT00164450·158 enrolled

Interaction3 trials

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

Completed·GGlobal Alliance for TB Drug Development·Phase 1·NCT02216331·32 enrolled

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Completed· Sanofi logo

Sanofi·Phase 1·NCT01690403·25 enrolled

Doravirine, Rifapentine and Isoniazid Interaction

Completed·WWalter K. Kraft·Phase 1·NCT03886701·11 enrolled

FAP2 trials

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

Completed·CCenters for Disease Control and Prevention·N/A·NCT00023387·36 enrolled

Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine

Terminated·JJohns Hopkins University·Phase 1·NCT00460759·15 enrolled

Prevention2 trials

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

Recruiting·—·Phase 1·NCT06281834·25 enrolled

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT01404312·3,000 enrolled

TED1 trial

The Correlate of Risk Targeted Intervention Study

Unknown status·UUniversity of Cape Town·Phase 2/3·NCT02735590·2,927 enrolled

10 more indications

Tics1 trial

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

Active, not recruiting·TThe Aurum Institute NPC·Phase 1/2·NCT05122026·252 enrolled

Mycobacterium Avium Complex1 trial

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.

Completed·AAnderson Clinical Research·Phase 2·NCT00002192

Single Dose1 trial

Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT01574638·44 enrolled

Children1 trial

Shortened Regimen for Drug-susceptible TB in Children

Recruiting·JJohns Hopkins University·Phase 3·NCT06253715·860 enrolled

Adult Subject1 trial

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

Withdrawn·YYale University·Phase 4·NCT04551573

Women1 trial

Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02651259·50 enrolled

Drug Interactions1 trial

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04272242·37 enrolled

Tenofovir1 trial

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT03510468·51 enrolled

HIV1 trial

A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04311502·104 enrolled

Unspecified1 trial

Video Based Directly Observed Therapy for Latent TB

Withdrawn·SSt. Louis University··NCT03783728

Regulatory

FDA Approval Timeline[5]

Jun 22, 1998

PRIFTIN

NDA NDA021024

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Rifapentine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Priftin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Rifapentine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Rifapentine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021024). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bacterial DNA-Directed RNA Polymerase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sanofi

Related News